PEN (Penumbra) Current Accrued Expense: $172 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PEN Penumbra Inc PEN
89 GF Score
Price $327.17
GF Value $332.90
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Penumbra Current Accrued Expense?

Penumbra PEN +0.05% 89 Current Accrued Expense is $172 Mil as of Jun. 2026. GuruFocus rates PEN with a GF Score™ of 89/100 and a GF Value™ of $332.90 (Fairly Valued). The stock has 2 warning signs investors should review.

Penumbra's Current Accrued Expense for the quarter that ended in Jun. 2026 was $172 Mil.

Penumbra's quarterly Current Accrued Expense increased from Dec. 2025 ($132 Mil) to Mar. 2026 ($152 Mil) and increased from Mar. 2026 ($152 Mil) to Jun. 2026 ($172 Mil).

Penumbra's annual Current Accrued Expense increased from Dec. 2023 ($104 Mil) to Dec. 2024 ($112 Mil) and increased from Dec. 2024 ($112 Mil) to Dec. 2025 ($132 Mil).

Penumbra Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Penumbra's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Penumbra Current Accrued Expense Chart

Penumbra Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.80 97.14 103.57 112.43 132.16

Penumbra Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 114.39 124.27 132.16 151.54 172.27
PEN
89GF Score
Penumbra Inc PEN
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Penumbra Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $172 Mil mean?
Penumbra (PEN) has a Current Accrued Expense of $172 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Penumbra and its competitors.
Is Penumbra's Current Accrued Expense too high?
Penumbra's current Current Accrued Expense is $172 Mil. Overall, Penumbra has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's Current Accrued Expense compare to PODD and GMED?
Penumbra's Current Accrued Expense of $172 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Penumbra and its competitors. Penumbra's current Current Accrued Expense is $172 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (PEN) is currently considered Fairly Valued. The stock's GF Value™ is $332.90, compared to a current price of $327.17 — trading 1.7% below its estimated fair value. The current Current Accrued Expense is $172 Mil. Penumbra's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Penumbra (PEN), the current Current Accrued Expense is $172 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Penumbra (PEN) Overvalued in 2026?

Based on GuruFocus' analysis, Penumbra stock appears to be undervalued. The current stock price of $327.17 is trading 1.7% below its estimated GF Value™ of $332.90. GuruFocus considers Penumbra to be Fairly Valued.

Key valuation signals for PEN:

  • Current Accrued Expense: $172 Mil
  • GF Value™: $332.90 vs. price of $327.17 (1.7% below fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Penumbra Business Description

Other Exchanges 0P8:Germany
Address 1310 Harbor Bay Parkway, One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
89GF Score

Get the complete analysis for PEN

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$327.17
Price
$332.90
GF Value